LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Actinium Pharmaceuticals Inc

Closed

1.7 -6.08

Overview

Share price change

24h

Current

Min

1.62

Max

1.82

Key metrics

By Trading Economics

Income

-9.3M

-16M

EPS

-0.51

Employees

31

EBITDA

-9.3M

-17M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+227.87% upside

Dividends

By Dow Jones

Next Earnings

1 Aug 2025

Market Stats

By TradingEconomics

Market Cap

7.5M

56M

Previous open

7.78

Previous close

1.7

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

21 May 2025, 23:25 UTC

Hot Stocks

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 May 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 May 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Operations in Uruguay

21 May 2025, 21:01 UTC

Major Market Movers

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 May 2025, 20:51 UTC

Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 May 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 May 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 May 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 May 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 May 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 May 2025, 23:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 May 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 May 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 May 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 May 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 May 2025, 23:28 UTC

Earnings

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 May 2025, 23:27 UTC

Earnings

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 May 2025, 23:23 UTC

Acquisitions, Mergers, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 May 2025, 23:22 UTC

Acquisitions, Mergers, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 May 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 May 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 May 2025, 21:42 UTC

Top News
Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 May 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Ops in Uruguay

21 May 2025, 21:07 UTC

Top News

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 May 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 May 2025, 20:59 UTC

Top News

Walmart to Cut 1,500 Jobs -- WSJ

21 May 2025, 20:52 UTC

Earnings

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

227.87% upside

12 Months Forecast

Average 6 USD  227.87%

High 9 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.